Owhofasa Agbedia, MD, MPH, FACP
@fasaagbedia.bsky.social
Hematologist/Medical Oncologist | Hematological malignancies | Posts/opinions are mine ≠ medical advice #lymsm #OncSky
huCART19-IL18 for lymphomas after anti-CD19 CART
CRS 62%
ICANS 14% (all gr 1/2)
ORR at 3mo 81%
CR at 3mo 52%
Med DOR 9.6 mo,
Med PFS 8.7mo
OS 86%
*Higher peak expansion and antitumor efficacy in pts with prior CD28 vs. 4-1BB-based CAR🤔
*🚫 HLH👏🏾 #lymsm
www.nejm.org/doi/full/10....
CRS 62%
ICANS 14% (all gr 1/2)
ORR at 3mo 81%
CR at 3mo 52%
Med DOR 9.6 mo,
Med PFS 8.7mo
OS 86%
*Higher peak expansion and antitumor efficacy in pts with prior CD28 vs. 4-1BB-based CAR🤔
*🚫 HLH👏🏾 #lymsm
www.nejm.org/doi/full/10....
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore...
www.nejm.org
May 7, 2025 at 11:03 PM
huCART19-IL18 for lymphomas after anti-CD19 CART
CRS 62%
ICANS 14% (all gr 1/2)
ORR at 3mo 81%
CR at 3mo 52%
Med DOR 9.6 mo,
Med PFS 8.7mo
OS 86%
*Higher peak expansion and antitumor efficacy in pts with prior CD28 vs. 4-1BB-based CAR🤔
*🚫 HLH👏🏾 #lymsm
www.nejm.org/doi/full/10....
CRS 62%
ICANS 14% (all gr 1/2)
ORR at 3mo 81%
CR at 3mo 52%
Med DOR 9.6 mo,
Med PFS 8.7mo
OS 86%
*Higher peak expansion and antitumor efficacy in pts with prior CD28 vs. 4-1BB-based CAR🤔
*🚫 HLH👏🏾 #lymsm
www.nejm.org/doi/full/10....
Inhibiting EZH1/2 increases the efficacy of CAR-T and TCR-T cells in preclinical models of both liquid and solid cancers👏🏾👏🏾👏🏾
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Porazzi et al. highlight how inhibiting the epigenetic regulators EZH2 and EZH1 enhances
cancer cell immunogenicity, boosting the effectiveness of CAR- and TCR-engineered
T cells across liquid and sol...
www.cell.com
March 11, 2025 at 9:20 PM
Inhibiting EZH1/2 increases the efficacy of CAR-T and TCR-T cells in preclinical models of both liquid and solid cancers👏🏾👏🏾👏🏾
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
CAR-T for T cell malignancies: the future is bright! 👏🏾👏🏾 #lymsm #CART ashpublications.org/bloodadvance...
December 28, 2024 at 2:05 PM
CAR-T for T cell malignancies: the future is bright! 👏🏾👏🏾 #lymsm #CART ashpublications.org/bloodadvance...
#ASH24 LBA-1
Tafa+Len+R for r/r FL
N=548, med fu 14m
⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾
Consistent benefit in all subgrps including POD24 (32% of study)!!,
CR 49.4% vs 39.8%
ORR 83.5% vs 72.4%
Med DOR 21.2m vs 13.6m
Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...
Tafa+Len+R for r/r FL
N=548, med fu 14m
⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾
Consistent benefit in all subgrps including POD24 (32% of study)!!,
CR 49.4% vs 39.8%
ORR 83.5% vs 72.4%
Med DOR 21.2m vs 13.6m
Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...
Paper: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
ash.confex.com
November 25, 2024 at 3:59 PM
#ASH24 LBA-1
Tafa+Len+R for r/r FL
N=548, med fu 14m
⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾
Consistent benefit in all subgrps including POD24 (32% of study)!!,
CR 49.4% vs 39.8%
ORR 83.5% vs 72.4%
Med DOR 21.2m vs 13.6m
Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...
Tafa+Len+R for r/r FL
N=548, med fu 14m
⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾
Consistent benefit in all subgrps including POD24 (32% of study)!!,
CR 49.4% vs 39.8%
ORR 83.5% vs 72.4%
Med DOR 21.2m vs 13.6m
Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...
Precision oncology for ECD, a rare disease with limited treatment options👏🏾👏🏾
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations | JCO Precision Oncology
PURPOSEBRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as
Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making
these treatments less effect...
ascopubs.org
November 24, 2024 at 2:15 AM
Precision oncology for ECD, a rare disease with limited treatment options👏🏾👏🏾
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...